172 related articles for article (PubMed ID: 29146517)
1. Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions.
Moghimi SM
Drug Discov Today; 2018 May; 23(5):1034-1042. PubMed ID: 29146517
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine.
La-Beck NM; Islam MR; Markiewski MM
Front Immunol; 2020; 11():603039. PubMed ID: 33488603
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement?
Szebeni J
Drug Discov Today; 2018 Mar; 23(3):487-492. PubMed ID: 29326077
[TBL] [Abstract][Full Text] [Related]
4. Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth.
Moghimi SM
J Control Release; 2014 Sep; 190():556-62. PubMed ID: 24746624
[TBL] [Abstract][Full Text] [Related]
5. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines.
Szebeni J; Bedőcs P; Csukás D; Rosivall L; Bünger R; Urbanics R
Adv Drug Deliv Rev; 2012 Dec; 64(15):1706-16. PubMed ID: 22820530
[TBL] [Abstract][Full Text] [Related]
6. Perspectives on complement and phagocytic cell responses to nanoparticles: From fundamentals to adverse reactions.
Moghimi SM; Haroon HB; Yaghmur A; Hunter AC; Papini E; Farhangrazi ZS; Simberg D; Trohopoulos PN
J Control Release; 2023 Apr; 356():115-129. PubMed ID: 36841287
[TBL] [Abstract][Full Text] [Related]
7. Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization.
Mészáros T; Kozma GT; Shimizu T; Miyahara K; Turjeman K; Ishida T; Barenholz Y; Urbanics R; Szebeni J
Int J Nanomedicine; 2018; 13():6345-6357. PubMed ID: 30349254
[TBL] [Abstract][Full Text] [Related]
8. Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model.
Jackman JA; Mészáros T; Fülöp T; Urbanics R; Szebeni J; Cho NJ
Nanomedicine; 2016 May; 12(4):933-943. PubMed ID: 26767512
[TBL] [Abstract][Full Text] [Related]
9. Drug-Induced Pseudoallergy: A Review of the Causes and Mechanisms.
Zhang B; Li Q; Shi C; Zhang X
Pharmacology; 2018; 101(1-2):104-110. PubMed ID: 29136631
[TBL] [Abstract][Full Text] [Related]
10. Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro.
Mészáros T; Csincsi ÁI; Uzonyi B; Hebecker M; Fülöp TG; Erdei A; Szebeni J; Józsi M
Nanomedicine; 2016 May; 12(4):1023-1031. PubMed ID: 26733258
[TBL] [Abstract][Full Text] [Related]
11. Complement Propriety and Conspiracy in Nanomedicine: Perspective and a Hypothesis.
Moghimi SM
Nucleic Acid Ther; 2016 Apr; 26(2):67-72. PubMed ID: 26720796
[TBL] [Abstract][Full Text] [Related]
12. Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes.
Wibroe PP; Anselmo AC; Nilsson PH; Sarode A; Gupta V; Urbanics R; Szebeni J; Hunter AC; Mitragotri S; Mollnes TE; Moghimi SM
Nat Nanotechnol; 2017 Jul; 12(6):589-594. PubMed ID: 28396605
[TBL] [Abstract][Full Text] [Related]
13. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals.
Szebeni J
Mol Immunol; 2014 Oct; 61(2):163-73. PubMed ID: 25124145
[TBL] [Abstract][Full Text] [Related]
14. Translational gaps in animal models of human infusion reactions to nanomedicines.
Moghimi SM; Simberg D
Nanomedicine (Lond); 2018 May; 13(9):973-975. PubMed ID: 29790401
[TBL] [Abstract][Full Text] [Related]
15. Liposome-induced hypersensitivity reactions: Risk reduction by design of safe infusion protocols in pigs.
Fülöp T; Kozma GT; Vashegyi I; Mészáros T; Rosivall L; Urbanics R; Storm G; Metselaar JM; Szebeni J
J Control Release; 2019 Sep; 309():333-338. PubMed ID: 31295544
[TBL] [Abstract][Full Text] [Related]
16. Genomic perspectives in inter-individual adverse responses following nanomedicine administration: The way forward.
Moghimi SM; Wibroe PP; Helvig SY; Farhangrazi ZS; Hunter AC
Adv Drug Deliv Rev; 2012 Oct; 64(13):1385-93. PubMed ID: 22634158
[TBL] [Abstract][Full Text] [Related]
17. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents.
Szebeni J
Crit Rev Ther Drug Carrier Syst; 2001; 18(6):567-606. PubMed ID: 11789676
[TBL] [Abstract][Full Text] [Related]
18. Immunological risk of injectable drug delivery systems.
Jiskoot W; van Schie RM; Carstens MG; Schellekens H
Pharm Res; 2009 Jun; 26(6):1303-14. PubMed ID: 19247815
[TBL] [Abstract][Full Text] [Related]
19. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles.
Szebeni J; Alving CR; Rosivall L; Bünger R; Baranyi L; Bedöcs P; Tóth M; Barenholz Y
J Liposome Res; 2007; 17(2):107-17. PubMed ID: 17613700
[TBL] [Abstract][Full Text] [Related]
20. Biological voyage of solid lipid nanoparticles: a proficient carrier in nanomedicine.
Ali H; Singh SK
Ther Deliv; 2016 Oct; 7(10):691-709. PubMed ID: 27790956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
